Ascentage Pharma (HKG:6855) presented the results of five preclinical studies at the meeting of the American Association for Cancer Research in Chicago, according to a Monday filing with the Hong Kong bourse.
The presentations, in poster form, are for its olverembatinib and lisaftoclax drugs for acute myeloid leukemia, as well as APG-5918 for prostate cancer, APG-2449 for small-cell lung cancer, and AS03157 for apoptosis protein inhibition or cell death prevention, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.